Breast implant and cosmetic surgery supplier Mentor corporation (MNT) was acquired by Johnson & Johnson (JNJ) for $1.1 billion on December 1st.
During the recent market turmoil, Mentor attempted to increase sales of its silicone implants, which have generated roughly twice the income of saline implants since their approval for the American market two years ago.
While the vast majority of Mentor’s income is in breast implants, they have decided to pursue a new wrinkle fighting, injectable drug derived from the botulinum toxin. The new injectable known as PurTox, will place
them in direct competition with Botox manufacturer Allergan Inc. The drug is expected to receive FDA approval in mid 2010.
